Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independent Director

Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors. She succeeds Philippe Archinard, who is retiring from the Board.